[18F]AH111585-PET, pazopanib, paclitaxel in ovarian cancer

• Research type

  Research Study

• Full title

  Phase 1b exploratory study of [18F]AH111585-PET as a marker of angiogenic response to combination therapy with the pan-VEGF inhibitor, pazopanib, and weekly paclitaxel in platinum resistant ovarian cancer

• IRAS ID

  46242

• Contact name

  Rohini Sharma

• Sponsor organisation

  Imperial College of Science Technology and Medicine, St. Mary's Campus

• Eudract number

  2009-017993-19

• ISRCTN Number

  2

• Research summary

  We are interested in treating tumours by stopping the abnormal blood vessels that supply nutrients to the cancer. Pazopanib is a new drug in tablet form that mainly targets the blood vessels supplying the tumour. Paclitaxel is a type of chemotherapy that is used to treat cancers and has been shown not only to shrink cancers but also target the abnormal blood vessels that supply nutrients to the cancer. We are studying the effect of the combination treatment on ovarian cancers resistant to chemotherapy. We have a type of scan that will help us see the changes in the blood vessels that feed the cancer cells after treatment. We have a type of scan that will help us see the changes in the tumour with the treatment.It will tell us if the blood vessels that help feed the cancer cells are being affected by the chemotherapy.We will also be investigating the changes that occur to the ovarian cancer by looking at differences in your tumour size before you start chemotherapy and and after 9 and 18 weeks. These will be compared to the PET scan to look for any changes in tumour size. Secondly, tissue samples from the cancer will be examined for research purposes and compared to PET images

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  14/ES/1003

• Date of REC Opinion

  22 Sep 2010

• REC opinion

  Further Information Favourable Opinion